Although CXCL9/10-DC monotherapy promotes T cell infiltration to the tumor margin, combination therapy with anti-PD-1 enhances T cell infiltration into the tumor and augments their proliferation and activity, resulting in the establishment of tumor-specific immunity. Here, CXCL9 is linked to neoplasm.